Overall survival benefit for patients with Stage III soft tissue sarcomas
Saturday, May 31, 2014 - 01:30
in Health & Medicine
The first retrospective analysis of adjuvant chemotherapy's impact on overall survival in patients with stage III soft tissue sarcomas (STS) has been conducted, adjusted for socioeconomic status and other variables. The findings show that regardless of socioeconomic status and comorbidities, adjuvant chemotherapy improved survival by approximately 23 percent in stage III STS.